Drug Profile


Alternative Names: A 45975; Blavin; Flotrin; Heitrin; Hitrin; Hyron; Hytracin; Hytrin; Hytrinex; Isontyn; Itrin; MY 208; Sinalfa; Teraprost; Urodie; Vasocard; Vasomet

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Abbott Laboratories
  • Developer Abbott Japan; Abbott Laboratories; Il-Yang; Kowa Pharmaceutical; Mitsubishi Chemical
  • Class Antihypertensives; Piperazines; Quinazolines; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Benign prostatic hyperplasia; Hypertension

Most Recent Events

  • 17 Feb 2014 Biomarkers information updated
  • 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
  • 03 Nov 2006 Nikken Chemicals is now called Kowa Pharmaceutical
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top